Validating laboratory results in a national observational cohort study without field centers: The reasons for geographic and racial differences in stroke cohort

Clinical Biochemistry

Volumn 47, Issue 16-17, 2014, Pages 243-246

  Gillett, Sarah R ^a   Boyle, Rebekah H ^a   Zakai, Neil A ^a   McClure, Leslie A ^b   Jenny, Nancy S ^a   Cushman, Mary ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biological markers; Blood chemical analysis; Blood specimen collection; Cohort studies; Quality control

Indexed keywords

BLOOD; BLOOD SAMPLING; COHORT ANALYSIS; HUMAN; LABORATORY DIAGNOSIS; PROCEDURES; STANDARDS; STROKE; UNITED STATES;

BLOOD SPECIMEN COLLECTION; COHORT STUDIES; HUMANS; SPECIMEN HANDLING; STROKE; UNITED STATES;

EID: 84908671280     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.08.003     Document Type: Article

References (14)

1. Holland N.T., Smith M.T., Eskenazi B., Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat Res 2003, 543:217-234.
2. Hulka B.S., Margolin B.H. Methodological issues in epidemiologic studies using biologic markers. Am J Epidemiol 1992, 135:200-209.
3. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995, 41:264-270.
4. Pai J.K., Curhan G.C., Cannuscio C.C., Rifai N., Ridker P.M., Rimm E.B. Stability of novel plasma markers associated with cardiovascular disease: processing within 36hours of specimen collection. Clin Chem 2002, 48:1781-1784.
5. Engbers M.J., Cushman M., Rosendaal F.R., Van Hylckama Vlieg A. The effect of time between venipuncture, processing and freezing on the measurement of coagulation factor levels. J Thromb Haemost 2012, 10:1691-1693.
6. Howard V.J., Cushman M., Pulley L., Gomez C.R., Go R.C., Prineas R.J., et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005, 25:135-143.
7. Tracy R., Bovill E., Stump D., Lin T., Gomol T., Collen D., et al. Reduction of in vitro artifact during blood collection in TIMI II. Blood 1988, 78:1.
8. Harrison P., Martin Cramer E. Platelet α-granules. Blood Rev 1993, 7:52-62.
9. Liu L., Choi H., Bernardo A., Bergeron A.L., Nolasco L., Ruan C., et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005, 3:2536-2544.
10. Booth N.A., Simpson A.J., Croll A., Bennett B., MacGregor I.R. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988, 70:327-333.
11. Kaplan R.C., Ho G.Y.F., Xue X., Rajpathak S., Cushman M., Rohan T.E., et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomark Prev 2007, 16:1291-1293.
12. Kotsopoulos J., Tworoger S.S., Campos H., Chung F.L., Clevenger C.V., Franke A.A., et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010, 19:938-946.
13. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
14. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.